{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:06:24Z","timestamp":1770743184792,"version":"3.49.0"},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Insight into predictors of cardiac involvement in inflammatory myopathies is sparse. A negative prognostic role of anti-mitochondrial antibodies (AMA) has been noticed and is supported by the current case. We describe a male patient who at the age 40 suffered a cardiac arrest and over the following months experienced progressive heart failure, arrhythmias and proximal muscle weakness. Clinical, genetic and serologic testing and repeated imaging- and histopathological investigations resulted in a diagnosis of AMA-associated, necrotizing, inflammatory myositis with cardiac involvement. Besides a cardiac resynchronization therapy defibrillator, heart failure and antiarrhythmic drugs the patient received successive immunosuppressants, which improved skeletal muscle strength but not cardiac disease progression. At age 45 he died from end-stage heart failure. Clinicians must be aware of AMA-associated myositis as a cause of unclarified heart disease, even in patients with initially sparse extra-cardiac manifestations. Further knowledge of treatment strategies is highly needed for this disease entity.<\/jats:p>","DOI":"10.1093\/omcr\/omaa150","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T06:30:10Z","timestamp":1615444210000},"source":"Crossref","is-referenced-by-count":12,"title":["Cardiac arrest in anti-mitochondrial antibody associated inflammatory myopathy"],"prefix":"10.1093","volume":"2021","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8046-263X","authenticated-orcid":false,"given":"Pil","family":"H\u00f8jgaard","sequence":"first","affiliation":[{"name":"Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Diseases, Rigshospitalet, University of Copenhagen, Denmark"},{"name":"Division of Rheumatology, Department of Internal Medicine, Holb\u00e6k Hospital, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanna","family":"Witting","sequence":"additional","affiliation":[{"name":"Copenhagen Neuromuscular Centre, Department of Neurology, Rigshospitalet, University of Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasper","family":"Rossing","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, University of Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Redi","family":"Pecini","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, University of Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hartvig Lindk\u00e6r Jensen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Rigshospitalet, University of Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Hasbak","sequence":"additional","affiliation":[{"name":"Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, University of Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise P","family":"Diederichsen","sequence":"additional","affiliation":[{"name":"Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Diseases, Rigshospitalet, University of Copenhagen, Denmark"},{"name":"Department of Rheumatology, Odense University Hospital, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"key":"2021031106181516600_ref1","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/brain\/aws106","article-title":"Inflammatory myopathies associated with anti-mitochondrial antibodies","volume":"135","author":"Maeda","year":"2012","journal-title":"Brain"},{"key":"2021031106181516600_ref2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.semarthrit.2017.06.004","article-title":"Inflammatory myopathy associated with anti-mitochondrial antibodies: a distinct phenotype with cardiac involvement","volume":"47","author":"Albayda","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2021031106181516600_ref3","first-page":"1468","article-title":"Myopathy with mitochondrial alterations in patients with primary biliary cirrhosis and antimitochondrial antibodies","volume":"36","author":"Varga","year":"1993","journal-title":"Arthritis Rheum"},{"key":"2021031106181516600_ref4","doi-asserted-by":"publisher","first-page":"1604.e9","DOI":"10.1016\/j.cjca.2019.07.002","article-title":"Variable cardiac responses to immunosuppressive therapy in anti-mitochondrial antibody-positive myositis","volume":"35","author":"Bujo","year":"2019","journal-title":"Can J Cardiol"},{"key":"2021031106181516600_ref5","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-218469","article-title":"Antimitochondrial antibodies-positive myositis accompanied by cardiac involvement","author":"Yamanaka","year":"2017","journal-title":"BMJ Case Rep"},{"key":"2021031106181516600_ref6","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehw403","article-title":"Lethal heart failure with anti-mitochondrial antibody: an arrhythmogenic right ventricular cardiomyopathy","author":"Koyama","year":"2016","journal-title":"Eur Heart J"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/omcr\/article-pdf\/2021\/3\/omaa150\/36513529\/omaa150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/omcr\/article-pdf\/2021\/3\/omaa150\/36513529\/omaa150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T06:59:24Z","timestamp":1615445964000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omaa150\/6161396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omaa150","relation":{},"ISSN":["2053-8855"],"issn-type":[{"value":"2053-8855","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3]]},"published":{"date-parts":[[2021,3,1]]},"article-number":"omaa150"}}